Affiliation:
1. DOKUZ EYLÜL ÜNİVERSİTESİ, İZMİR ULUSLARARASI BİYOTIP VE GENOM ENSTİTÜSÜ, GENOM BİLİMLERİ VE MOLEKÜLER BİYOTEKNOLOJİ ANABİLİM DALI
2. DOKUZ EYLÜL ÜNİVERSİTESİ, İZMİR ULUSLARARASI BİYOTIP VE GENOM ENSTİTÜSÜ
Abstract
Purpose: The global pandemic COVID-19, caused by the coronavirus SARS-CoV-2, is persistent despite the increasing vaccination rates, with new cases being reported per week. MicroRNAs, that is, non-coding RNA species that regulate gene expression at the post-transcriptional level, play a pivotal role in the SARS-CoV-2 life cycle, pathophysiology and host’s anticoronaviral responses. The objective of this study was the in silico discovery of functionally associated miRNAs that likely co-regulate COVID-19-related genes
Materials and Methods: In the present study, an integrative bioinformatics approach was employed, including database searching, gene set enrichment analysis, network-based and microRNA target prediction methods, towards the discovery of epigenetic determinants of COVID-19.
Results: An intricate microRNA-target gene network was constructed, and a set of 8 highly interacting microRNAs, that potentially co-target and co-regulate key COVID-19-related genes, was detected. These miRNAs and their corresponding genes are likely involved in the host’s response to SARS-CoV-2 infection.
Conclusion: The 8 functionally associated miRNAs could constitute a signature for COVID-19 diagnosis.
Reference82 articles.
1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/.
2. Mahase E. Covid-19: New "Pirola" variant BA.2.86 continues to spread in UK and US. BMJ. 2023;382:2097.
3. Satapathy P, Kumar P, Gupta JK, Rabaan AA, Al Kaabi NA, Mohanty D et al. The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health. Int J Surg. 2024.
4. Abdolreza E, Fereshteh E, Armin JM, Amir S. EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19. Infection. 2024.
5. Zhang L, Kempf A, Nehlmeier I, Cossmann A, Richter A, Bdeir N et al. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell. 2024.